A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic Fibrosis

Cystic Fibrosis Clinical Trial

Official title:

A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Pulmozyme® in 3- to 5-Year-Old Patients With Cystic Fibrosis

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00680316
• Other study ID #: Z4240g
• Status: Terminated
• Phase: Phase 4
• First received: May 16, 2008
• Last updated: May 18, 2011
• Start date: June 2008
• Est. completion date: May 2009

Study information

• Verified date: May 2011
• Source: Genentech, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This was a Phase IV, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the effect of Pulmozyme on pulmonary function, health-related quality of life (HRQOL), and respiratory symptoms in 3- to 5-year-old children with cystic fibrosis (CF). Approximately 40 patients were planned to be enrolled in this study. However, only 3 patients were eligible for random allocation and received treatment: 1 patient in the Pulmozyme group and 2 patients in the placebo group. All 3 patients completed the study assessments but did not have usable pulmonary function test (PFT) data.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 3
• Est. completion date: May 2009
• Est. primary completion date: May 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 3 Years to 5 Years

Eligibility

Inclusion Criteria:

• Signed Informed Consent Form

• Aged 3-5 years

• Diagnosis of cystic fibrosis

Exclusion Criteria:

• Children taking scheduled inhaled Pulmozyme or hypertonic saline within 56 days prior to Visit 1 or any Pulmozyme in the 28 days before Visit 1

• Involvement in a clinical intervention trial within the 4 weeks prior to Visit 1

• Use of an investigational drug or device within 28 days prior to Visit 1

• Any other condition that might increase the risk of participation to the patient in the judgement of the investigator

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cystic Fibrosis
• Fibrosis

Intervention

Drug:
• Dornase alfa
2.5 mL (2.5 mg) dornase alfa nebulized once daily for 16 (+/-2) days
• Placebo
2.5 mL (2.5 mg) placebo nebulized once daily for 16 (+/-2) days

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Genentech, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Reactance at 8 Hz (Xrs8) From Visit 2 to Visit 3 (Change From Baseline at Visit 2 to Visit 3, After Study Drug Treatment).	The fundamental principle of forced oscillometry is that lung function can be assessed by measuring changes in pressure and flow in response to external pressure applied at the airway opening. Reactance is complex measure that incorporates the changes in pressure and volume and the rate of these changes in response to pressure oscillations at a specific frequency. (8Hz was used for the primary endpoint). Reactance is thought to reflect the elastic properties of the lung.	from Visit 2 to Visit 3 (16 +/- 2 days)	No
Secondary	Change in Reactance at 4, 6, and 10 Hz (Xrs4, Xrs6, and Xrs10)	The fundamental principle of forced oscillometry is that lung function can be assessed by measuring changes in pressure and flow in response to external pressure applied at the airway opening. Reactance is complex measure that incorporates the changes in pressure and volume and the rate of these changes in response to pressure oscillations at a specific frequency. (8Hz was used for the primary endpoint). Reactance is thought to reflect the elastic properties of the lung.	from Visit 2 to Visit 3 (16 +/- 2 days)	No
Secondary	Change in Resistance at 4, 6, 8, and 10 Hz (Rrs4, Rrs6, Rrs8, and Rrs10)	The fundamental principle of forced oscillometry is that lung function can be assessed by measuring changes in pressure and flow in response to external pressure applied at the airway opening. Resistance is complex measure that incorporates the lack of changes in pressure and volume and the rate of these changes in response to pressure oscillations at a specific frequency. (10Hz was used for the secondary endpoint).	from Visit 2 to Visit 3 (16 +/- 2 days)	No
Secondary	Change in Respiratory Symptom Domain Score From the Cystic Fibrosis Questionnaire Revised (CFQ-R) for Parents of Preschoolers and for Preschoolers	The CFQ-R for Preschoolers and the CFQ-R for Parents of Preschoolers was designed specifically to measure the impact of CF for patients with a diagnosis of CF. Each question is answered using a 4-point Likert scale.; In order to calculate the domain/symptom scale scores, the following algorithm is followed; Re-number items which have been reverse coded; Calculate the mean of the items to be included. If more than half of the items are missing, then the score is considered missing; Re-scale to result in a scaled score which ranges from 0 to 100, with higher scores indicating better health	from Visit 2 to Visit 3 (16 +/- 2 days)	No